Zhong Lun Law Firm and O’Melveny & Myers have advised Chinese drug development service provider Pharmaron on its $588 million Hong Kong IPO, with JunHe and Skadden Arps Slate Meagher & Flom advising the joint sponsors.

Founded in 2004, Pharmaron is a fully integrated pharmaceutical research and development platform assisting on drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.

The Zhong Lun team was led by partners Tingfeng Hu and Chuan Wang; the OMM team was led by partners Portia Ku, Ke Zhu and Edwin Kwok; the JunHe team was led by partner Yi Wang; the Skadden team was led by partners Julie Gao and Paloma Wang.